Role of microRNAs in gastric cancer

Table 1 Aberrant expression of miRNAs in gastric cancer

Up-regulated miRNAs

let-7a, miR-9, -10a, -10b, -17, -17-5p, -18a, -18b, -19a, -19b, -20a, -20b, -21, -23a, -23b

miR-25, -26b, -27, -29b-1, -30b, -31, -34a, -34b, -34c, -92, -98, -99a, -100, -103, -106a

miR-106b, -107, -125b, -126, -128a, -130b, -138, -142-3p, -146a, -147, -150, -151-5p

miR-155, 181a, -181a-2, -181b, -181c, -185, -191, -192, -194, -196a, -196b, -199a

miR-199a-3p, -200b, -210, -214, -215, -221, -222, -223, -296-5p

miR-301a, -302f, -337-3p, -340, -370, -421, -520c-3p, -575, -601, -616, -658, -1259

Down-regulated miRNAs

let-7a, -7f, miR-7, -9, -22, -29c, -30a-5p, -31, -34a, -34b, -34c

miR-101, -126, -128b, -129, -129-2, -129-3p, -130b, -133b, -135a, -137, -141, -145

miR-146a, -148, -148b, -149, -152, -155, -181b, -181c, -182, -193b, -195, -195-5p, -197

miR-200, -204, -206, -210, -212, -218, -219-2-3p, -302b, -331-3p, -375

miR-378, -408-3p, -429, -433, -486, -495, -551a, -574-3p, -610, -622, -638, -663, -874

Table 2 miRNAs associated with prognosis in gastric cancer patients

let-7a ,-7i

miR-10b, -20a, -20b, -21, -22, -25, -27a, -30a-5p, -34a, -93

miR-103, -106a, -106b, -107, -125a-5p, -126, -130, -142-5p, -144, -146a, -150

miR-155, -181c, -195, -196a, -199a-3p, -200c, -206, -221, -222, -223

miR-335, -338, -372, -375, -451

Table 3 MiRNAs involved in chemosensitivity

5FU sensitivity

let-7g

miR-10b, -22, -30c, -31, -32,

miR-133b, -143, -144, -145, -181b, -190, -197, -200c, -204, -210

miR-335, -501, -501-5p, -532, -615, -615-5p, -766, -877

miR-1224-3p, -1229, -3131, -3149, -3162-3p, -4763-3p

CPT sensitivity

let-7g

miR-7, -31, -98, -126, -196a, -200, -338

CDDP, CF sensitivity

let-7g

miR-1, -16, -21, -34, -181, -181b, -342, -497

Table 4 Circulating miRNAs as biomarkers

Up-regulated miRNAs

miR-1, -17, -17-5p, -20a, -21, -27a, -31, -34, -103, -106a, -106b, -107,-194, -200c

miR-210, -221, -223, -370, -376a, -378, 421, 423-5p, 451, -486, 744

Down-regulated miRNAs

miR-218, -375